Analysts Offer Predictions for Lantheus Holdings, Inc.’s Q2 2024 Earnings (NASDAQ:LNTH)

Lantheus Holdings, Inc. (NASDAQ:LNTH) – B. Riley issued their Q2 2024 earnings per share (EPS) estimates for Lantheus in a research note issued on Wednesday, June 26th. B. Riley analyst Y. Zhi anticipates that the medical equipment provider will earn $1.67 per share for the quarter. B. Riley has a “Buy” rating and a $99.00 price objective on the stock. The consensus estimate for Lantheus’ current full-year earnings is $6.46 per share. B. Riley also issued estimates for Lantheus’ Q3 2024 earnings at $1.49 EPS, Q4 2024 earnings at $1.52 EPS and FY2024 earnings at $6.18 EPS.

Several other analysts have also commented on the company. Truist Financial increased their price objective on Lantheus from $82.00 to $96.00 and gave the company a “buy” rating in a report on Friday, May 3rd. Mizuho raised their target price on Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, May 3rd. Finally, StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and an average price target of $99.17.

Lantheus Stock Performance

Shares of LNTH opened at $78.50 on Monday. Lantheus has a 12 month low of $50.20 and a 12 month high of $91.81. The stock has a fifty day moving average price of $78.03 and a 200-day moving average price of $65.96. The company has a current ratio of 4.84, a quick ratio of 4.55 and a debt-to-equity ratio of 0.59. The firm has a market cap of $5.44 billion, a PE ratio of 11.98 and a beta of 0.51.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.51 EPS for the quarter, beating the consensus estimate of $1.40 by $0.11. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. The firm had revenue of $369.98 million during the quarter, compared to analyst estimates of $349.46 million.

Institutional Investors Weigh In On Lantheus

Several institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC boosted its holdings in Lantheus by 184.1% in the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 208 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in Lantheus by 47.8% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 9,805 shares of the medical equipment provider’s stock worth $586,000 after buying an additional 3,171 shares during the last quarter. Aurora Investment Counsel boosted its holdings in Lantheus by 32.9% in the 1st quarter. Aurora Investment Counsel now owns 32,539 shares of the medical equipment provider’s stock worth $2,025,000 after buying an additional 8,047 shares during the last quarter. Boston Partners boosted its holdings in Lantheus by 21.2% in the 1st quarter. Boston Partners now owns 681,281 shares of the medical equipment provider’s stock worth $42,696,000 after buying an additional 119,156 shares during the last quarter. Finally, Cetera Advisors LLC purchased a new position in Lantheus in the 1st quarter worth approximately $565,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $76.89, for a total transaction of $26,219.49. Following the sale, the chief accounting officer now directly owns 62,898 shares of the company’s stock, valued at approximately $4,836,227.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $76.89, for a total transaction of $26,219.49. Following the sale, the chief accounting officer now directly owns 62,898 shares in the company, valued at approximately $4,836,227.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Heinz Christoph Maeusli sold 18,373 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $79.19, for a total value of $1,454,957.87. Following the sale, the director now owns 23,340 shares in the company, valued at $1,848,294.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,269 shares of company stock valued at $2,557,300. Company insiders own 2.10% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.